<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">mrj</journal-id><journal-title-group><journal-title xml:lang="ru">Современная ревматология</journal-title><trans-title-group xml:lang="en"><trans-title>Modern Rheumatology Journal</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1996-7012</issn><issn pub-type="epub">2310-158X</issn><publisher><publisher-name>IMA-PRESS, LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.14412/1996-7012-2022-2-87-91</article-id><article-id custom-type="elpub" pub-id-type="custom">mrj-1280</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОБЗОРЫ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>REVIEWS</subject></subj-group></article-categories><title-group><article-title>Проблема длительного контроля боли при хронических ревматических заболеваниях</article-title><trans-title-group xml:lang="en"><trans-title>The problem of long-term pain control in chronic rheumatic diseases</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5103-5447</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Полищук</surname><given-names>Е. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Polishchuk</surname><given-names>E. Yu.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Елена Юрьевна Полищук</p><p>Россия, 115522, Москва, Каширское шоссе, 34А</p></bio><bio xml:lang="en"><p>Elena Yurievna Polishchuk</p><p>34A, Kashirskoe shosse, Moscow 115522, Russia</p></bio><email xlink:type="simple">dr.pogozheva@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1391-0711</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Каратеев</surname><given-names>А. Е.</given-names></name><name name-style="western" xml:lang="en"><surname>Karateev</surname><given-names>A. E.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Россия, 115522, Москва, Каширское шоссе, 34А</p></bio><bio xml:lang="en"><p>34A, Kashirskoe shosse, Moscow 115522, Russia</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>V.A. Nasonova Research Institute of Rheumatology</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2022</year></pub-date><pub-date pub-type="epub"><day>06</day><month>05</month><year>2022</year></pub-date><volume>16</volume><issue>2</issue><fpage>87</fpage><lpage>91</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Полищук Е.Ю., Каратеев А.Е., 2022</copyright-statement><copyright-year>2022</copyright-year><copyright-holder xml:lang="ru">Полищук Е.Ю., Каратеев А.Е.</copyright-holder><copyright-holder xml:lang="en">Polishchuk E.Y., Karateev A.E.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://mrj.ima-press.net/mrj/article/view/1280">https://mrj.ima-press.net/mrj/article/view/1280</self-uri><abstract><p>Боль является одним из основных симптомов и наиболее тягостным проявлением ревматических заболеваний (РЗ). В настоящее время нестероидные противовоспалительные препараты (НПВП) широко используются для симптоматического лечения РЗ в реальной клинической практике, однако эффективность и переносимость их продолжительного приема остаются недостаточно изученными. Многие пациенты с РЗ нуждаются в длительном использовании НПВП. При этом следует учитывать наличие коморбидной патологии и факторов риска развития лекарственных осложнений, поэтому выбор НПВП должен основываться прежде всего на соображениях безопасности пациента. Ацеклофенак (Аэртал®) обладает выраженным анальгетическим потенциалом и хорошим профилем безопасности, что позволяет рекомендовать его для длительного приема.</p></abstract><trans-abstract xml:lang="en"><p>Pain is one of the main symptoms and the most distressing manifestation of rheumatic diseases (RD). Currently, non-steroidal anti-inflammatory drugs (NSAIDs) are widely used for the symptomatic treatment of RD in real clinical practice, but the effectiveness and tolerability of their longterm use remain insufficiently studied. Many patients with RD require long-term use of NSAIDs. In this case, the presence of comorbid pathology and risk factors for the development of drug complications should be taken into consideration, so the choice of NSAIDs should be based primarily on considerations of patient safety. Aceclofenac (Aertal®) has a pronounced analgesic potential and a good safety profile, which allows us to recommend it for long-term use.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>нестероидные противовоспалительные препараты</kwd><kwd>длительный прием</kwd><kwd>ацеклофенак (Аэртал®)</kwd><kwd>эффективность</kwd><kwd>безопасность</kwd></kwd-group><kwd-group xml:lang="en"><kwd>non-steroidal anti-inflammatory drugs</kwd><kwd>long-term use</kwd><kwd>aceclofenac (Aertal®)</kwd><kwd>efficiency</kwd><kwd>safety</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Насонов ЕЛ, редактор. Российские клинические рекомендации. Ревматология. Москва: ГЭОТАР-Медиа; 2020. 448 с.</mixed-citation><mixed-citation xml:lang="en">Nasonov EL, editor. Rossiiskie klinicheskie rekomendatsii. Revmatologiya [Russian clinical guidelines. Rheumatology]. Moscow: GEOTAR-Media; 2020. 448 p.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Steffen А, Holstiege J, Klimke K, et al. Patterns of the initiation of disease-modifying antirheumatic drugs in incident rheumatoid arthritis: a German perspective based on nationwide ambulatory drug prescription data. Rheumatol Int. 2018 Nov;38(11):2111-20. doi: 10.1007/s00296-018-4161-7. Epub 2018 Oct 10.</mixed-citation><mixed-citation xml:lang="en">Steffen А, Holstiege J, Klimke K, et al. Patterns of the initiation of disease-modifying antirheumatic drugs in incident rheumatoid arthritis: a German perspective based on nationwide ambulatory drug prescription data. Rheumatol Int. 2018 Nov;38(11):2111-20. doi: 10.1007/s00296-018-4161-7. Epub 2018 Oct 10.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Black RJ, Richards B, Lester S, et al. Factors associated with commencing and ceasing opioid therapy in patients with rheumatoid arthritis. Semin Arthritis Rheum. 2019 Dec;49(3):351-7. doi: 10.1016/j.semarthrit.2019.06.003</mixed-citation><mixed-citation xml:lang="en">Black RJ, Richards B, Lester S, et al. Factors associated with commencing and ceasing opioid therapy in patients with rheumatoid arthritis. Semin Arthritis Rheum. 2019 Dec;49(3):351-7. doi: 10.1016/j.semarthrit.2019.06.003</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Kimsey L, Weissman JS, Patel A, et al. Delay in initiation of DMARD or anti-inflammatory therapy in patients newly diagnosed with rheumatoid arthritis: An analysis of United States Military Health System TRICARE beneficiaries. Semin Arthritis Rheum. 2019 Apr;48(5):821-7. doi: 10.1016/j.semarthrit.2018.07.003.</mixed-citation><mixed-citation xml:lang="en">Kimsey L, Weissman JS, Patel A, et al. Delay in initiation of DMARD or anti-inflammatory therapy in patients newly diagnosed with rheumatoid arthritis: An analysis of United States Military Health System TRICARE beneficiaries. Semin Arthritis Rheum. 2019 Apr;48(5):821-7. doi: 10.1016/j.semarthrit.2018.07.003.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Crossfield SSR, Buch MH, Baxter P, Kingsbury SR, Pujades-Rodriguez M, Conaghan PG. Changes in the pharmacological management of rheumatoid arthritis over two decades. Rheumatology (Oxford). 2021 Sep 1; 60(9):4141-51. doi: 10.1093/rheumatology/keaa892.</mixed-citation><mixed-citation xml:lang="en">Crossfield SSR, Buch MH, Baxter P, Kingsbury SR, Pujades-Rodriguez M, Conaghan PG. Changes in the pharmacological management of rheumatoid arthritis over two decades. Rheumatology (Oxford). 2021 Sep 1; 60(9):4141-51. doi: 10.1093/rheumatology/keaa892.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Каратеев АЕ, Погожева ЕЮ, Амирджанова ВН и др. Регулярный прием нестероидных противовоспалительных препаратов позволяет эффективно контролировать боль и общее самочувствие у пациентов с умеренной активностью ревматоидного артрита. Современная ревматология. 2021;15(2):57-63.</mixed-citation><mixed-citation xml:lang="en">Karateev AE, Pogozheva EYu, Amirdzhanova VN, et al. Regular use of non-steroidal anti-inflammatory drugs can effectively control pain and global health in patients with moderate activity of rheumatoid arthritis. Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2021;15(2):57-63. (In Russ.). doi: 10.14412/1996-7012-2021-2-57-63.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Лила АМ, Алексеева ЛИ, Таскина ЕА. Современные подходы к терапии остеоартрита с учетом обновленных международных рекомендаций. Русский медицинский журнал. 2019;(3):48-52.</mixed-citation><mixed-citation xml:lang="en">Lila AM, Alekseeva LI, Taskina EA. Modern approaches to the treatment of osteoarthritis taking into account the updated international recommendations. Russkii meditsinskii zhurnal. 2019;(3):48-52. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Collins JE, Katz JN, Dervan EE, Losina E. Trajectories and risk profiles of pain in persons with radiographic, symptomatic knee osteoarthritis: data from the osteoarthritis initiative. Osteoarthritis Cartilage. 2014 May;22(5):622-30. doi: 10.1016/j.joca.2014.03.009. Epub 2014 Mar 21.</mixed-citation><mixed-citation xml:lang="en">Collins JE, Katz JN, Dervan EE, Losina E. Trajectories and risk profiles of pain in persons with radiographic, symptomatic knee osteoarthritis: data from the osteoarthritis initiative. Osteoarthritis Cartilage. 2014 May;22(5):622-30. doi: 10.1016/j.joca.2014.03.009. Epub 2014 Mar 21.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Curtis SP, Bockow B, Fisher C, et al. Etoricoxib in the treatment of osteoarthritis over 52-weeks: a double-blind, active-comparator controlled trial [NCT00242489]. BMC Musculoskelet Disord. 2005 Dec 1;6:58. doi: 10.1186/1471-2474-6-58.</mixed-citation><mixed-citation xml:lang="en">Curtis SP, Bockow B, Fisher C, et al. Etoricoxib in the treatment of osteoarthritis over 52-weeks: a double-blind, active-comparator controlled trial [NCT00242489]. BMC Musculoskelet Disord. 2005 Dec 1;6:58. doi: 10.1186/1471-2474-6-58.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Dahlberg LE, Holme I, Høye K, Ringertz B. A randomized, multicentre, doubleblind, parallel-group study to assess the adverse event-related discontinuation rate with celecoxib and diclofenac in elderly patients with osteoarthritis. Scand J Rheumatol. Mar-Apr 2009;38(2):133-43. doi: 10.1080/03009740802419065.</mixed-citation><mixed-citation xml:lang="en">Dahlberg LE, Holme I, Høye K, Ringertz B. A randomized, multicentre, doubleblind, parallel-group study to assess the adverse event-related discontinuation rate with celecoxib and diclofenac in elderly patients with osteoarthritis. Scand J Rheumatol. Mar-Apr 2009;38(2):133-43. doi: 10.1080/03009740802419065.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Pelletier JP, Raynauld JP, Beaulieu AD, et al. Chondroitin sulfate efficacy versus celecoxib on knee osteoarthritis structural changes using magnetic resonance imaging: a 2-year multicentre exploratory study. Arthritis Res Ther. 2016 Nov 3;18(1):256. doi: 10.1186/s13075-016-1149-0.</mixed-citation><mixed-citation xml:lang="en">Pelletier JP, Raynauld JP, Beaulieu AD, et al. Chondroitin sulfate efficacy versus celecoxib on knee osteoarthritis structural changes using magnetic resonance imaging: a 2-year multicentre exploratory study. Arthritis Res Ther. 2016 Nov 3;18(1):256. doi: 10.1186/s13075-016-1149-0.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Reginster J, Malmstrom K, Mehta A, et al. Evaluation of the efficacy and safety of etoricoxib compared with naproxen in two, 138-week randomised studies of patients with osteoarthritis. Ann Rheum Dis. 2007 Jul;66(7):945-51. doi: 10.1136/ard.2006.059162. Epub 2006 Dec 1.</mixed-citation><mixed-citation xml:lang="en">Reginster J, Malmstrom K, Mehta A, et al. Evaluation of the efficacy and safety of etoricoxib compared with naproxen in two, 138-week randomised studies of patients with osteoarthritis. Ann Rheum Dis. 2007 Jul;66(7):945-51. doi: 10.1136/ard.2006.059162. Epub 2006 Dec 1.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Langdon CG, Moran DG, Jamieson V, et al. A multicentre study of tenoxicam for the treatment of osteo-arthritis and rheumatoid arthritis in general practice. J Int Med Res. Nov-Dec 1990;18(6):489-96. doi: 10.1177/030006059001800607.</mixed-citation><mixed-citation xml:lang="en">Langdon CG, Moran DG, Jamieson V, et al. A multicentre study of tenoxicam for the treatment of osteo-arthritis and rheumatoid arthritis in general practice. J Int Med Res. Nov-Dec 1990;18(6):489-96. doi: 10.1177/030006059001800607.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Schattenkirchner M. Long-term safety of ketoprofen in an elderly population of arthritic patients. Scand J Rheumatol Suppl. 1991; 91:27-36. doi: 10.3109/03009749109096948.</mixed-citation><mixed-citation xml:lang="en">Schattenkirchner M. Long-term safety of ketoprofen in an elderly population of arthritic patients. Scand J Rheumatol Suppl. 1991; 91:27-36. doi: 10.3109/03009749109096948.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Гайдукова ИЗ, Ребров АП, Лапшина СА, и др. Применение нестероидных противовоспалительных препаратов и генно-инженерных биологических препаратов для лечения аксиальных спондилоартритов. Рекомендации Экспертной группы по изучению спондилоартритов при Общероссийской общественной организации «Ассоциация ревматологов России». Научно-практическая ревматология. 2017;55(5):</mixed-citation><mixed-citation xml:lang="en">Gaidukova IZ, Rebrov AP, Lapshina SA, et al. The use of nonsteroidal anti-inflammatory drugs and genetically engineered biological drugs for the treatment of axial spondyloarthritis. Recommendations of the Expert Group on the study of spondyloarthritis at the All-Russian Public Organization «Association of Rheumatologists of Russia». Nauchnoprakticheskaya revmatologiya. 2017;55(5):474-84. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">-84.</mixed-citation><mixed-citation xml:lang="en">Van der Heijde D, Ramiro S, Landew R, et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis. 2017 Jun; 76(6):978-91. doi: 10.1136/annrheumdis- 2016-210770. Epub 2017 Jan 13.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Van der Heijde D, Ramiro S, Landew R, et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis. 2017 Jun; 76(6):978-91. doi: 10.1136/annrheumdis- 2016-210770. Epub 2017 Jan 13.</mixed-citation><mixed-citation xml:lang="en">Ward MM, Deodhar A, Gensler LS, et al. 2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. Arthritis Care Res (Hoboken). 2019 Oct; 71(10):1285-99. doi: 10.1002/acr.24025.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Ward MM, Deodhar A, Gensler LS, et al. 2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. Arthritis Care Res (Hoboken). 2019 Oct; 71(10):1285-99. doi: 10.1002/acr.24025.</mixed-citation><mixed-citation xml:lang="en">Erdes ShF. Recent advances and prospects of axial spondyloarthritis / ankylosing spondylitis treatment. Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2021;15(2):94-105. (In Russ.). doi: 10.14412/1996-7012-2021-2-94-105</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Эрдес ШФ. Последние достижения и перспективы терапии аксиального спондилоартрита / анкилозирующего спондилита. Современная ревматология. 2021; 15(2):94-105.</mixed-citation><mixed-citation xml:lang="en">Iolascon G, Gimйnez S, Mogyorуsi D. A Review of Aceclofenac: Analgesic and AntiInflammatory Effects on Musculoskeletal Disorders. J Pain Res. 2021 Nov 30;14:3651-63. doi: 10.2147/JPR.S326101. eCollection 2021.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Iolascon G, Gimйnez S, Mogyorуsi D. A Review of Aceclofenac: Analgesic and AntiInflammatory Effects on Musculoskeletal Disorders. J Pain Res. 2021 Nov 30;14:3651-63. doi: 10.2147/JPR.S326101. eCollection 2021.</mixed-citation><mixed-citation xml:lang="en">Patel PB, Patel TK. Efficacy and safety of aceclofenac in osteoarthritis: a meta-analysis of randomized controlled trials. Eur J Rheumatol. 2017 Mar;4(1):11-8. doi: 10.5152/eurjrheum.2017.160080. Epub 2017 Mar 1.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Patel PB, Patel TK. Efficacy and safety of aceclofenac in osteoarthritis: a meta-analysis of randomized controlled trials. Eur J Rheumatol. 2017 Mar;4(1):11-8. doi: 10.5152/eurjrheum.2017.160080. Epub 2017 Mar 1.</mixed-citation><mixed-citation xml:lang="en">Castellsague J, Riera-Guardia N, Calingaert B, et al. Individual NSAIDs and upper gastrointestinal complications: a systematic review and meta-analysis of observational studies (the SOS project). Drug Saf. 2012 Dec 1; 35(12):1127-46. doi: 10.2165/11633470-000000000-00000.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Castellsague J, Riera-Guardia N, Calingaert B, et al. Individual NSAIDs and upper gastrointestinal complications: a systematic review and meta-analysis of observational studies (the SOS project). Drug Saf. 2012 Dec 1; 35(12):1127-46. doi: 10.2165/11633470-000000000-00000.</mixed-citation><mixed-citation xml:lang="en">Masclee GMC, Straatman H, Arfи A, et al. Risk of acute myocardial infarction during use of individual NSAIDs: A nested casecontrol study from the SOS project. PLoS One. 2018 Nov 1;13(11):e0204746. doi: 10.1371/journal.pone.0204746. eCollection 2018.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Masclee GMC, Straatman H, Arfи A, et al. Risk of acute myocardial infarction during use of individual NSAIDs: A nested casecontrol study from the SOS project. PLoS One. 2018 Nov 1;13(11):e0204746. doi: 10.1371/journal.pone.0204746. eCollection 2018.</mixed-citation><mixed-citation xml:lang="en">Karateev AE, Tsurkan AV. Aceclofenac: the experience of Russian research. Sovremennaiya revmatologiya = Modern Rheumatology Journal. 2017;11(4):89-94. (In Russ.). doi:10.14412/1996-7012-2017-4-89-94.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Каратеев АЕ, Цуркан АВ. Ацеклофенак: опыт российских исследований. Современная ревматология. 2017;11(4):89-94.</mixed-citation><mixed-citation xml:lang="en">Karateev AE, Polishchuk EYu, Filatova ES, et al. Long-term use of nonsteroidal anti-inflammatory drugs for pain control in patients with osteoarthritis: results of the 12-month observational study AELITA (Analgesia: Effective Treatment Using The Therapeutic Algorithm). Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2021;15(6):84-90. (In Russ.). doi: 10.14412/1996-7012-2021-6-84-90</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Каратеев АЕ, Полищук ЕЮ, Филатова ЕС и др. Длительное использование нестероидных противовоспалительных препаратов для контроля боли у пациентов с остеоартритом: результаты 12-месячного наблюдательного исследования АЭЛИТА (Аналгезия: Эффективное Лечение с Использованием Терапевтического Алгоритма). Современная ревматология. 2021;15(6):84-90.</mixed-citation><mixed-citation xml:lang="en">Каратеев АЕ, Полищук ЕЮ, Филатова ЕС и др. Длительное использование нестероидных противовоспалительных препаратов для контроля боли у пациентов с остеоартритом: результаты 12-месячного наблюдательного исследования АЭЛИТА (Аналгезия: Эффективное Лечение с Использованием Терапевтического Алгоритма). Современная ревматология. 2021;15(6):84-90.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
